Onshoring is not about abandoning global integration, it’s about recalibrating it. For biotech companies, the goal is a resilient, adaptive manufacturing network that balances efficiency with control. Domestic production can strengthen regulatory trust, accelerate delivery, and protect intellectual property, but it must be pursued with clear strategy and disciplined execution.

Below, we’ll explore this evolution and how leaders can approach onshoring decisions with clarity and confidence.

The onshoring decision framework

Onshoring decisions should never hinge on a single data point or incentive package. The right approach depends on a company’s pipeline, risk tolerance, and strategic horizon. Leaders should structure decisions through a multi-dimensional lens.

• Start with portfolio analysis
  • Which products are most exposed to supply-chain volatility or geopolitical risk? Which stages of production yield the greatest value from proximity—R&D scale-up, clinical batches, or commercial supply? A quantitative risk-reward matrix helps prioritize where domestic investment delivers the strongest return.
    
• Consider partial onshoring
  • Many organizations begin with hybrid models—retaining offshore bulk production but bringing formulation, packaging, or QC testing closer to market. This approach builds resilience incrementally without overextending capital.
    
• Build, partner, or hybridize
  • Building new facilities grants full control but requires significant capital and time. Partnering with contract development and manufacturing organizations (CDMOs) can accelerate readiness but may limit flexibility. Increasingly, companies are forming co-investment models that blend both—jointly developing sites with CDMOs or state entities to share cost and capability.
    
• Maintain flexibility through scenario planning
  • Policy and market conditions evolve quickly. Running multiple what-if scenarios—modeling cost, capacity, and risk over five- to ten-year horizons—helps prevent over-commitment. Decision frameworks should include trigger points for expansion or diversification as incentives, regulations, or market demands shift.
    
• Institutionalize learning
  • Organizations that treat onshoring as an ongoing capability rather than a one-off project build durable advantage. Capturing lessons from early projects, codifying them into playbooks, and embedding them into governance processes ensures each subsequent build or transfer is faster and more efficient.

What’s next for biotech onshoring

Over the next few years, the differentiators will be companies that move deliberately — those that pair technical foresight with operational realism. Monitoring policy developments, automation technologies, and workforce dynamics will be critical to staying ahead.

At Harmony Biotech Consulting, we help clients navigate every step of the onshoring journey, from strategic modeling and site selection to regulatory validation and operational scale-up. With deep expertise across biotech manufacturing, regulatory affairs, and quality systems, our team empowers organizations to build the manufacturing ecosystems of tomorrow — stronger, smarter, and closer to home.